Mainz Biomed N.V. (NASDAQ: MYNZ) rocketed higher Wednesday morning, and for good reason. The company, one that specializes in the early detection of cancer, announced that it entered into an agreement with Socpra Sciences Santé Et Humaines S.E.C. surrounding access to novel mRNA biomarkers.
MYNZ Stock Gains On New Biomarker Access
As mentioned above, Mainz Biomed said it entered into a Technology Rights Agreement with Socpra Sciences Santé Et Humaines S.E.C. that provides access to a portfolio of novel mRNA biomarkers for potential future integration into ColoAlert.
ColoAlert is the company’s easy-to-use test for colorectal cancer, one that has proven to be highly efficacious. Currently, the ColoAlert test is available in Europe, but it may soon be available in the United States. In fact, MYNZ said it’s preparing to initiate ColoAlert’s regulatory pathway for approval in the United States.
This article originally appeared at CNA Finance.